OTCPK:NVSEF (Switzerland)  
Novartis AG logo

Novartis AG

$ 75.77 0 (0%) 10:08 PM EST
P/E:
7.98
P/B:
2.70
Market Cap:
$ 169.07B
Enterprise V:
$ 180.39B
Volume:
43.31K
Avg Vol (2M):
68.82K
Also Trade In:
Volume:
43.31K
Market Cap $:
169.07B
PE Ratio:
7.98
Avg Vol (2-Month):
68.82K
Enterprise Value $:
180.39B
PB Ratio:
2.70
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Financials (Next Earnings Date:2022-10-25)

NVSEF's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:NVSEF

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 52,788
EPS (TTM) ($) 10.22
Beta 0.62
Volatility % 21.3
14-Day RSI 39.1
14-Day ATR ($) 1.221091
20-Day SMA ($) 77.874256
12-1 Month Momentum % 5.22
52-Week Range ($) 72.98 - 93.575
Shares Outstanding (Mil) 2,182.79

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Novartis AG Filings

Document Form Filing Date
No Filing Data

Novartis AG Analysis

Share your research

Headlines

See More
No news.